May 25, 2022

Exogenous leptin enhances markers of airway fibrosis in a mouse model of chronic allergic airways disease

  • Research
  • Open Access

Background

Asthma patients with comorbid obesity exhibit increased disease severity, in part, due to airway remodeling, which is also observed in mouse models of asthma and obesity. A mediator of remodeling that is increased in obesity is leptin. We hypothesized that in a mouse model of allergic airways disease, mice receiving exogenous leptin would display increased airway inflammation and fibrosis.

Methods

Five-week-old male and female C57BL/6J mice were challenged with intranasal house dust mite (HDM) allergen or saline 5 days per week for 6 weeks (n = 6–9 per sex, per group). Following each HDM exposure, mice received subcutaneous recombinant human leptin or saline.

May 23, 2022

Use of JAK Inhibitors in AD: The Allergist’s Perspective.Tweetorial. CME

May 21, 2022

Increased expression of IL1-RL1 is associated with type 2 and type 1 immune pathways in asthma

  • Research
  • Open Access

Background

Asthma is a common chronic airway disease in the world. The purpose of this study was to explore the expression of IL1-RL1 in sputum and its correlation with Th1 and Th2 cytokines in asthma.

May 20, 2022

Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life

Abstract

Background

Biologics are currently one of the main treatment options for a number of diseases. The IgG4 monoclonal antibody dupilumab targets the Interleukin-4 receptor alpha chain, thus preventing the biological effects of the cytokines IL-4 and IL-13, that are essential for the Th2 response. Several controlled trials showed that dupilumab is effective and safe in patients with atopic dermatitis (AD), severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), thus resulting in approval by regulatory agencies.

May 17, 2022

Th1 cytokines synergize to change gene expression and promote corticosteroid insensitivity in pediatric airway smooth muscle

  • Research
  • Open Access

Abstract

Background

Corticosteroids remain a key therapy for treating children with asthma. Patients with severe asthma are insensitive, resistant, or refractory to corticosteroids and have poorly controlled symptoms that involve airway inflammation, airflow obstruction, and frequent exacerbations. While the pathways that mediate corticosteroid insensitivity in asthma remain poorly defined, recent studies suggest that enhanced Th1 pathways, mediated by TNFα and IFNγ, may play a role. We previously reported that the combined effects of TNFα and IFNγ promote corticosteroid insensitivity in developing human airway smooth muscle (ASM).

May 16, 2022

Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride

  • Review
  • Open Access

Objective

The present narrative review provides a comprehensive update of the current knowledge on urticaria, both in adult and pediatric populations, and on the safety and efficacy of fexofenadine hydrochloride (HCl) as a treatment option.

Data source

A literature search was conducted on Embase and Medline.

Study selection

Clinical studies published in English and published between 1999 and 2020 were selected.

May 11, 2022

Facial Dermatoses and Use of Protective Mask During Covid-19 Pandemic: A Clinical and Psychological Evaluation in Patients Affected by Moderate-Severe Atopic Dermatitis Under Treatment With Dupilumab

Vanessa M, Elia E, Federica V, Edoardo C, Chiara A, Francesca G, Paola S. Facial Dermatoses and Use of Protective Mask During Covid-19 Pandemic: A Clinical and Psychological Evaluation in Patients Affected by Moderate-Severe Atopic Dermatitis Under Treatment With Dupilumab. Dermatol Ther. 2022 May 10:e15573. doi: 10.1111/dth.15573. Epub ahead of print

ABSTRACT

BACKGROUND: During the SARS-COV-2 pandemic, using face masks became mandatory in many countries. Although evidence suggests that masks can exacerbate several inflammatory skin diseases, few studies focus on their real impact on eczema localized to the face in atopic dermatitis (AD) patients.

May 2, 2022

Asthma and comorbidities: recent advances

Cazzola M, Rogliani P, Ora J, et al. Asthma and comorbidities: recent advances. Pol Arch Intern Med. 2022; 132: 16250. doi:10.20452/pamw.16250

ABSTRACT

Asthma is usually associated with pulmonary and extrapulmonary comorbidities that are more common in patients with severe asthma than in those with mild-to-moderate illness or in the general population. These comorbidities may affect the clinical intensity and severity of asthma and, as a result, increase health care costs related to its therapy. On the other hand, their recognition and appropriate treatment appear to improve asthma outcomes while optimizing therapy by preventing overtreatment. Comorbid conditions such as gastroesophageal reflux disease, allergic rhinitis, obesity, depression, diabetes mellitus, and cardiovascular disease are commonly known, though their prevalence varies significantly between studies; however, many more comorbidities may remain undiagnosed and only be discovered in an experienced specialized environment.